Cumberland Pharmaceutical... (CPIX)
Cumberland Pharmaceuticals Statistics
Share Statistics
Cumberland Pharmaceuticals has 13.97M shares outstanding. The number of shares has increased by -0.95% in one year.
| Shares Outstanding | 13.97M |
| Shares Change (YoY) | -0.95% |
| Shares Change (QoQ) | -0.38% |
| Owned by Institutions (%) | 13.11% |
| Shares Floating | 7.79M |
| Failed to Deliver (FTD) Shares | 893 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 438.81K, so 3.12% of the outstanding shares have been sold short.
| Short Interest | 438.81K |
| Short % of Shares Out | 3.12% |
| Short % of Float | 5.59% |
| Short Ratio (days to cover) | 0.82 |
Valuation Ratios
The PE ratio is -5.14 and the forward PE ratio is 16.86. Cumberland Pharmaceuticals's PEG ratio is -1.13.
| PE Ratio | -5.14 |
| Forward PE | 16.86 |
| PS Ratio | 0.88 |
| Forward PS | 1.4 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | -1.13 |
Enterprise Valuation
Cumberland Pharmaceuticals Inc. has an Enterprise Value (EV) of 25.7M.
| EV / Earnings | -3.97 |
| EV / Sales | 0.68 |
| EV / EBITDA | -4 |
| EV / EBIT | -4 |
| EV / FCF | 0 |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.9.
| Current Ratio | 1.15 |
| Quick Ratio | 1.03 |
| Debt / Equity | 0.9 |
| Total Debt / Capitalization | 47.37 |
| Cash Flow / Debt | -0.03 |
| Interest Coverage | -10.62 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is 0%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | 0% |
| Revenue Per Employee | $416,131.26 |
| Profits Per Employee | $-71,206.26 |
| Employee Count | 91 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -22.67K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 144.13% in the last 52 weeks. The beta is -0.18, so Cumberland Pharmaceuticals's price volatility has been lower than the market average.
| Beta | -0.18 |
| 52-Week Price Change | 144.13% |
| 50-Day Moving Average | 4.4 |
| 200-Day Moving Average | 2.21 |
| Relative Strength Index (RSI) | 42.1 |
| Average Volume (20 Days) | 1.67M |
Income Statement
In the last 12 months, Cumberland Pharmaceuticals had revenue of 37.87M and earned -6.48M in profits. Earnings per share was -0.46.
| Revenue | 37.87M |
| Gross Profit | 31.28M |
| Operating Income | -6.43M |
| Net Income | -6.48M |
| EBITDA | -6.43M |
| EBIT | -6.43M |
| Earnings Per Share (EPS) | -0.46 |
Balance Sheet
The company has 17,964.2B in cash and 20,572.4B in debt, giving a net cash position of -2,608.2B.
| Cash & Cash Equivalents | 17,964.2B |
| Total Debt | 20,572.4B |
| Net Cash | -2,608.2B |
| Retained Earnings | -23,967.9B |
| Total Assets | 75.58M |
| Working Capital | 4.83M |
Cash Flow
In the last 12 months, operating cash flow was -612.19B and capital expenditures -66.46B, giving a free cash flow of -678.65B.
| Operating Cash Flow | -612.19B |
| Capital Expenditures | -66.46B |
| Free Cash Flow | -678.65B |
| FCF Per Share | -48266.99 |
Margins
Gross margin is 82.61%, with operating and profit margins of -16.99% and -17.11%.
| Gross Margin | 82.61% |
| Operating Margin | -16.99% |
| Pretax Margin | -17.08% |
| Profit Margin | -17.11% |
| EBITDA Margin | -16.99% |
| EBIT Margin | -16.99% |
| FCF Margin | -1.79M% |
Dividends & Yields
CPIX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10.53% |
| FCF Yield | -1111772.26% |
Analyst Forecast
Currently there are no analyst rating for CPIX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 0.56 |
| Piotroski F-Score | 5 |